?effect of Dapagliflozin in acute myocardial infarction

Investigating the effect of dapagliflozin compared to placebo on clinical indicators, laboratory indicators and cardiac performance indicators in acute myocardial infarction patients with a drop in ejection fraction undergoing primary angioplasty.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240730062583N1

Enrollment

100

Registered

2024-12-16

Start date

2024-05-14

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure. Heart failure

Interventions

Intervention 1: Intervention group 1: Dapagliflozin tablets ,from the sodium-glucose co-transporter inhibitor drug category , with a dose of 10 mg, one per day for 42 weeks, is received by Actoverco p

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: over 18 year old Acute myocardial infarction who undergoing primary PCI Ejection fraction (EF) < 50%

Exclusion criteria

Exclusion criteria: pregnancy previous heart failure kidney failure liver failure previous taking SGLT2i

Design outcomes

Primary

Measure	Time frame
Ejection function. Timepoint: baseline, 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: echocardiography.;Gobal strain longitudinal. Timepoint: baseline, 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Complete blood count. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a cell counting method.;Triglyceride. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Cholestrol. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Low density lipid. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;High density lipid. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Fasting blood suger. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Hemoglobin A1c. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Erythrocyte sedimentation rate. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;C-reactive protein. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Blood urea nitrogen. Timepoint: baseline, 6 weeks and 6 months later. Method of measurement: A venous blood sample taken from	—

Measure

Time frame

Complete blood count. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a cell counting method.;Triglyceride. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Cholestrol. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Low density lipid. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;High density lipid. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Fasting blood suger. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Hemoglobin A1c. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Erythrocyte sedimentation rate. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;C-reactive protein. Timepoint: baseline 6 weeks and 42 weeks after starting dapagliflozin. Method of measurement: A venous blood sample taken from a patient by a laboratory technician using a Mindray device.;Blood urea nitrogen. Timepoint: baseline, 6 weeks and 6 months later. Method of measurement: A venous blood sample taken from

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed sadr

Iran University of Medical Sciences

saeed.sadr94@gmail.com+98 21 86701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026